After turbulent years, Teva CEO Schultz forecasts stability
Teva completed its two-year major restructuring plan in 2019, reducing its cost base by over $3 billion and net debt by more than $9b.
Teva CEO Kåre Schultz at the Tel Aviv Stock Exchange, February 19, 2020(photo credit: SIVAN FARAG)